Crossmark

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Crossref DOI link: https://doi.org/10.1038/s43856-023-00290-0

Published Online: 2023-05-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rocconi, Rodney P. https://orcid.org/0000-0001-8642-5859
Stanbery, Laura

Tang, Min

Madeira da Silva, Luciana

Walter, Adam

Monk, Bradley J.

Herzog, Thomas J.

Coleman, Robert L.

Manning, Luisa

Wallraven, Gladice

Horvath, Staci https://orcid.org/0000-0003-0181-8448
Bognar, Ernest

Senzer, Neil

Brun, Scott

Nemunaitis, John https://orcid.org/0000-0002-2234-2381
License Information

Text and Data Mining valid from 2023-05-05

Version of Record valid from 2023-05-05
More Information

Article History

First Online: 5 May 2023

Document is current

Any future updates will be listed below